Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions
- PMID: 21481721
- DOI: 10.1016/j.ijrobp.2010.11.074
Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions
Abstract
Over the past 15 years, there have been three major advances in the use of external beam radiotherapy in the management of men with clinically localized prostate made. They include: (1) image guided (IG) three-dimensional conformal/intensity modulated radiotherapy; (2) radiation dose escalation; and (3) androgen deprivation therapy. To date only the last of these three advances have been shown to improve overall survival. The presence of occult pelvic nodal involvement could explain the failure of increased conformality and dose escalation to prolong survival, because the men who appear to be at the greatest risk of death from clinically localized prostate cancer are those who are likely to have lymph node metastases. This review discusses the evidence for prophylactic pelvic nodal radiotherapy, including the key trials and controversies surrounding this issue.
Copyright © 2011 Elsevier Inc. All rights reserved.
Comment in
-
Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions: in regard to Morikawa and Roach III (Int J Radiat Oncol Biol Phys 2011 May 1;80:6-16).Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1318; author reply 1318. doi: 10.1016/j.ijrobp.2011.11.061. Int J Radiat Oncol Biol Phys. 2012. PMID: 22385711 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
